Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Stage IV Melanoma: early-phase trial registry
A small indexed set (15 trials) with no open enrollment listed right now.
Corpus placement: #1,140 of 28,707 conditions by registered trial count.
15 US clinical trials · none currently recruiting · #1,140 of 28,707 conditions by registered trial count
Stage IV Melanoma: 15 US clinical trials tracked, none currently recruiting.
Stage IV Melanoma is the subject of 15 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 15 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 8 of these trials.
Enrollment posture brief
Registry condition stage-iv-melanoma
OPEN 0 | RECR 0% | LATE 0 | EARLY 15 | RANK #1140 | SPON 8
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Stage IV Melanoma has no open enrollment in this registry pull (15 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Stage IV Melanoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Stage IV Melanoma is recruiting below its size-band peers.
0 of 15 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Stage IV Melanoma research.
National Cancer Institute (NCI) accounts for 8 of 15 trials (53.3%). 7 distinct sponsors appear on at least one study for this condition label.
-
Most Stage IV Melanoma trials plan to enrol fewer than 100 people.
Median target enrolment is 40 among the 14 trials that report a genuine target (sentinel values excluded). 14 of those (100%) plan for fewer than 100 participants.
-
Stage IV Melanoma research is mostly interventional.
15 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Indexed trials (enrollment closed)
15 total, page 1 of 1
A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma
Elizabeth Buchbinder, MD
NCT04356729
Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients
Richard Wu
NCT05176470
E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma
Eisai
NCT01133977
Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma
Eisai
NCT01127451
Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
NCT00119249
Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma
National Cancer Institute (NCI)
NCT00349206
Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma
National Cancer Institute (NCI)
NCT00072163
Vaccine Plus Interleukin-2 in Treating Patients With Advanced Melanoma
National Cancer Institute (NCI)
NCT00005949
Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers
National Cancer Institute (NCI)
NCT00074308
Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma
Abramson Cancer Center at Penn Medicine
NCT01103635
Individualized Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
Mayo Clinic
NCT01328535
Decitabine in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
NCT00030615
Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid Tumors
National Cancer Institute (NCI)
NCT00112476
Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers
Case Comprehensive Cancer Center
NCT00498979
flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer
National Cancer Institute (NCI)
NCT00019396
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 8 |
| Phase 2 | 7 |
Top Sponsors
Named interventions
Most-linked intervention names on Stage IV Melanoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Stage IV Melanoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Stage IV Melanoma page
15 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Stage IV Melanoma trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- National Cancer Institute (NCI) sponsors the most Stage IV Melanoma trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Stage IV Melanoma condition card totals 15 registered trials; most-linked intervention laboratory biomarker analysis; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.